A phase II study of Tarceva [erlotinib] for untreated, good prognosis patients with advanced non-small cell lung cancer.
Latest Information Update: 29 Nov 2012
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 01 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Jan 2012 Planned End Date changed from 1 Dec 2011 to 1 Sep 2012 as reported by ClinicalTrials.gov.